Physician profile
Albert J Contento
NPI 1659473155
$9,532.14
in general payments reported to CMS, 2019-2025
23 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $1,012 · 2021: $2,251 · 2022: $1,330 · 2023: $1,323 · 2024: $1,258 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,337.38 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $1,267.92 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Johnson & Johnson Vision Care, INC. | $1,258.62 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $1,037.42 | 2019-2023 | |
| Abbvie INC. | $860.46 | 2022-2024 | Lumigan, Vuity, Alphagan P |
| Biotissue Holdings INC. | $656.64 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $507.76 | 2019-2021 | |
| Coopervision INC. | $371.24 | 2021-2025 | Myday Contact Lens |
| Alcon Vision LLC | $333.97 | 2019-2025 | Total30, Precision7, Tryptyr |
| Lumenis Be INC | $309.95 | 2025 | Optilight |
| Oyster Point Pharma, INC. | $294.82 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $259.83 | 2019-2025 | |
| Horizon Therapeutics Plc | $222.24 | 2023 | Tepezza |
| Amgen INC. | $173.51 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $170.90 | 2022-2023 | Omni Surgical System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $160.05 | 2019 | |
| Harrow Eye, LLC | $84.46 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $82.88 | 2020-2023 | Flarex |
| Aerie Pharmaceuticals, INC. | $48.46 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $47.09 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $17.15 | 2022 | |
| Ocular Therapeutix, INC. | $15.90 | 2022 | |
| Heidelberg Engineering, INC. | $13.49 | 2023 | Spectralis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Contento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.